Is Altimmune a Buy Before Phase III MASH Starts in 2026?

ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its ...
Taiwan News

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing of its previously announced underwritten public ...

INVENTIVA: Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor

Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva's organizational build-out as it advances toward potential commercialization.Axel-Sven Malkomes ...
Eater Boston on MSN

Boston’s best steakhouses

Where to eat steaks, chops, and creamed spinach around town ...

D&D Pharmatech to Unveil Phase 2 DD01 Clinical Trial Results for the First Time at EASL Congress

D&D Pharmatech, a company specializing in the development of GLP-1 (glucagon-like peptide-1) class novel drugs, announced on April 22 that it has ...

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducemen…

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting ...
Bristol Herald Courier

California bear-suit luxury car scam ends in insurance fraud sentences for 3

Suspects were accused of staging fake bear attacks in luxury cars and seeking almost $142,000 in payouts from insurance ...